Philip Scheltens
Prof. dr. Philip Scheltens studied at the VU University Amsterdam, Netherlands, gaining his MD in 1984, and PhD in 1993. He was appointed as Professor of Cognitive Neurology in 2000 and founded the Alzheimer Center at Amsterdam University Medical Centers in that same year, which he directed until 2022. Currently he is partner at EQT group and heads the Dementia Fund at EQT Life Sciences, that he started in 2020.
In his current job, he leads the Investment Team of the Fund and sits on the board of three portfolio companies: Aviado Bio, NOBI, AstronautX and is special advisor to New Amsterdam Pharma, the first company the team invested in, now listed at the NY Stock Exchange. Outside his daily work he chairs the scientific advisory board of the Alzheimer Center Amsterdam and is a member of the scientific advisory board of the Stichting ALS (NL), Julius Clinical (NL), the Swiss Synapsis Foundation, the Race Against Dementia Foundation (UK) and special member of the Geller Commission (UK).
He has been the (inter)national PI for over 35 studies, including phase 1-3 multicenter clinical trials. He supervised >100 PhD theses since 2000. He founded and led the Dutch National Plan against dementia and served as chair of the board until 2021. He currently sits on the advisory panel of the Dutch National Strategy for Dementia 2022-2030.
Philip served as co-editor-in-chief of Alzheimer’s Research & Therapy from 2013-2022 and co-led various EU projects. He authored over 1250 peer reviewed papers and > 75 book chapters and co-edited several major textbooks.
He is member of the Royal Dutch Academy of Arts and Sciences (KNAW) since 2011 and was member of the board from 2015-2020. In 2016 he was awarded the European Grand Prix for Alzheimer’s Research. In 2020 he was Knighted in the Order of the Netherlands Lion by the King of the Netherlands. In 2021 he was elected honorary member of the European Academy of Neurology. He also acts as chair of the World Dementia council since 2021. In 2023 he received the Bengt Winblad Lifetime Achievement Award for his lifelong dedication to the field of Alzheimer Research and Care.